Investigation of The Stability of 177LuPSMA-I&T Prostate-specific Membrane Antigen İnhibitor Used in The Treatment of Castration Resistant Prostate Cancer

Öz

Objective: Internalization of the prostate-specific membrane antigen (PSMA) by ligand binding through clathrin-coated vesicle followed by endocytosis provides it an excellent target in prostate cancer imaging Gallium-68 (68Ga) and treatment Lutetium-177 (177Lu). The purpose of this research is to examine the in-vitro stability of the radiopharmaceutical (177LuPSMA-I&T) labeled with 177Lu of PSMA-I&T in saline.
Material-Method: Labeling of PSMA-I&T with 177Lu was carried out in the automated synthesis module. The labeled 200mCi (7.4 GBq) 177LuPSMA-I&T was incubated at 37oC for 72 hours. Samples taken at regular intervals up to 72 hours were analyzed by radio-high performance liquid chromatography (RP-HPLC). Results: The radiochemical efficiency of 177LuPSMA-I&T was > 99%. We determined that 177LuPSMA-I&T prepared with PSMA-I&T remained stable up to 6 hours, and deteriorated by 3.1% at the 24th hour. Conclusions: With the easy and fast labeled 177LuPSMA-I&T radiopharmaceutical is safe to use in treatment due to its stability in the first 6 hours.

Anahtar Kelimeler

• Prostate-specific membrane antigen
• PSMA
• 177LuPSMA-I&T
• castration-resistant prostate cancer
• radionuclide therapy

Kastrasyona Dirençli Prostat Kanseri Tedavisinde Kullanılan 177LuPSMA-I&T’nin İnvitro Stabilitesinin İncelenmesi

Öz

Giriş: Prostat spesifik membran antijeni (PSMA), klatrin kaplı veziküller yoluyla hücreye bağlanır ve ardından endositoz yoluyla hücre içine girer. Bu özelliği nedeniyle, PSMA prostat kanseri görüntülemede Galyum-68 (68Ga) ve tedavide Lutesyum-177 (177Lu) ile işaretlenebilen mükemmel bir moleküldür. Çalışmanın amacı, PSMA-I&T'nin 177Lu ile işaretlenmiş radyofarmasötiğinin (177LuPSMA-I&T) serum fizyolojik içerisinde in-vitro stabilitesini incelemektir. Materyal-Metod: PSMA-I&T'nin 177Lu ile işaretlemesi otomatik sentez modulünde gerçekleştirildi. İşaretlenmiş 200mCi (7,4 GBq) 177LuPSMA-I&T 37oC'de 72 saat inkübasyona bırakıldı. 72. saate kadar belirli aralıklarla alınan örnekler radyo-yüksek performanslı sıvı kromatografisi (RP-HPLC) ile analiz edildi. Bulgular: 177LuPSMA-I&T'nin radyokimyasal verimi >% 99 bulundu. PSMA-I&T ile hazırlanan 177LuPSMA-I&T'nin ilk 6 saate kadar stabil kaldığı, 24. saatte ise stabilitesinde %3,3 oranında bozunumun başladığı, 48. saatten sonra ise kullanıma uygun olmadığı belirlendi. Sonuç: 177LuPSMA-I&T ile tedavide radyofarmasötiğin ilk 6.saatteki stabilitesi nedeniyle görüntüleme ve tedavide kullanımının daha güvenli olduğu, gerektiğinde etiketlemeden sonraki 48 saate kadar kullanılabileceği sonucuna varılmıştır.

Anahtar Kelimeler

• Prostata spesifik membran antijeni
• PSMA
• 177LuPSMA-I&T
• kastrasyona dirençli prostat kanseri
• radyonüklid tedavisi

Kaynakça

1. 1. Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011; 65:1180-92
2. 2. Hotte SJ, Saad F. Current management of castration resistant prostate cancer. Curr Oncol 2010; 17(2):72-79
3. 3. Kambali I. Production of Lu-177 Radionuclide using Deuteron Beams: Comparison between (d,n) and (d,p) Nuclear Reactions, in: Journal of Physics: Conference Series. 2018; 1120: 1-7.
4. 4. Hermanne A, Takacs S, Goldberg MB, Lavie E, Shubin YN, Kovalev S. Deuteron-induced reactions on Yb: Measured cross sections and rationale for production pathways of carrier-free, medically relevant radionuclides. Nucl. Instruments Methods Phys. Res. Sect. B Beam Interact. with Mater. Atoms, 2006; 247: 223–231.
5. 5. Manenti, S., Groppi, F., Gandini, A., Gini, L., Abbas, K., Holzwarth, U., Simonelli, F., Bonardi M. Excitation function for deuteron induced nuclear reactions on natural ytterbium for production of high specific activity 177gLu in no-carrier-added form for metabolic radiotherapy. Appl. Radiat. Isot., 2011; 69: 37–45.
6. 6. Handbook of chemistry: pure chemistry. 5th ed. Chemical Society of Japan; 2004
7. 7. Kuznetsov RA, Bobrovskayaа KS, Svetukhinа VV, Fominа AN, Zhukovа AV. Production of Lutetium-177: Process Aspects. Radiochem.. 2019; 61 (4): 381-95.
8. 8. Breeman WAP, de Jong M, Visser TJ, Erion JL, Krenning EP. Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities. Eur. J. Nucl. Med. Mol. Imag., 2003; 30 (6): 917-20.

9. 9. Dash A, Chakraborty S, Pillai MRA, Knapp FF. Peptide receptor radionuclide therapy: an overview. Cancer Biother Radiopharm, 2015; 30 (2): 47–71.
10. 10. Parus JL, Pawlak D, Mikoliajczak R, Duatti A. Chemistry and bifunctional chelating agents for binding (177)Lu. Curr Radiopharm. 2015; 8(2): 86-94.
11. 11. Zang J, Fan X, Wang H, Qingxing L, Jingnan W, Hui L et al. First-in-human study of 177LuEB-PSMA-617 in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging 2019; 46(1):148-58.
12. 12. von Eyben FE, Roviello G, Kiljunen T, Uprimny C, Virgolini I, Kairemo K et al. Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review. Eur J Nucl Med Mol Imaging 2018; 45:496-508.
13. 13. Rinker-Schaeffer CW, Hawkins AL, Su SL, Israeli RS, Griffin CA, Isaacs JT, Heston WD. Localization and physical mapping of the prostate-specific membrane antigen (PSM) gene to human chromosome 11+ Genomics. 1995; 30(1):105-08.
14. 14. Israeli RS, Powell CT, Fair WR, Heston WDW. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen, Cancer Res. 1993; 15;53(2):227-30.
15. 15. Emmett L, Willowson K, Violet J, Shin J, Blanksby A, Lee J. Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy. J Med Radiat Sci 2017;64:52-60.
16. 16. Kabasakal L, Toklu T, Yeyin N, Demirci E, Abuqbeitah M, Ocak M et.al. Lu-177-PSMA-617 Prostate-Specific Membrane Antigen Inhibitor Therapy in Patients with Castration-Resistant Prostate Cancer: Stability, Bio-distribution and Dosimetry, Mol Imaging Radionucl Ther. 2017; 26(2): 62–68.
17. 17. Ocak M, Helbok A, von Guggenberg E, Ozsoy Y, Kabasakal L, Kremser L, Decristoforo C, Influence of biological assay conditions on stability assessment of radiometal-labelled peptides exemplified using a 177Lu-DOTA-minigastrin derivative, Nuclear Medicine and Biology, 2011; 38(2), 171-179.
18. 18. Mather S. Preclinical development of therapeutic radiopharmaceuticals, IAEA Technical Reports Series No.458, Comparative evaluation of therapeutic radiopharmaceuticals 2007; 257-265.